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Immunosuppression and Cancer 
By Israel Penn and Thomas E. Starzl 
BESIDES their beneficial effect in retard-ing or arresting the growth of certain 
types of neoplasms, a number of anticancer 
drugs may cause impairment of antibody 
synthesis and cell-mediated immunity. 
These immunosuppressive effects have 
been used therapeutically to prevent and 
control rejection of organ homografts and 
also to treat a variety of clinical states. 
However, the anticancer agents have muta-
genic, teratogenic, and oncogenic properties 
in experimental animals and presumably 
also in humans. The present report is con-
cerned with their potential oncogenic ef-
fects in man. 
Evidence has been accumulated from 
three groups of patients about which full 
details are being published in Cancer.l 
It should be emphasized that the vast ma-
jority of the cases have been contributed 
to us or have appeared in the literature 
and did not come from our own center. 
The groups include (1) immunosuppressed 
organ transplant recipients; (2) patients 
with a variety of noncancerous diseases 
treated with immunosuppressive agents; 
(3) Patients with malignant tumors who re-
ceived cancer chemotherapy. 
ORGAN TRANSPLANT RECIPIENTS 
Since 1968 we have maintained an infor-
mal Tumor Registry in Denver to record 
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cases of cancer in organ homograft recip-
ients. l -4 Tumors were encountered in three 
groups of transplant patients. (1) those 
which arose de novo after transplantation; 
(2) those inadvertently transmitted with 
the homograft; and (3) those which were 
present before transplantation. 
Cancers Which Appeared After Trans-
plantation: An organ transplant recipient 
maintained on chronic immunosuppressive 
therapy has a 5-6% chance of developing 
a de novo cancer within the first few years 
after transplantation. l -4 We have collected 
details of 122 such cases from transplant 
centers throughout the world. The patients 
had 125 tumors of which 76 were of 
epithelial origin (61 %) and 49 (39%) were 
mesenchymal. 
The most common epithelial lesions were 
various skin cancers (27 cases, 36%), car-
cinomas of the cervix (11 cases, 14 %) and 
carcinomas of the lip (11 cases, 14%): The 
remainder consisted of a wide variety of 
visceral carcinomas, many of high-grade 
malignancy. 
Forty-two (86%) of the 49 mesenchymal 
tumors were solid lymphomas, of which 
the most prominent subgroup was reticu-
lum cell sarcoma (30 cases, 61%). A most 
unusual feature of the lymphomas was 
their predeliction for the central nervous 
system which occurred in 20 of 41 cases 
(49%). 
The cancers occurred at an average age 
of 36 yr. The mean time of appearance of 
the tumors after transplantation was 28 mo 
(range 1-92 mo). The possibility of trans-
plantation of cancer from the donors was 
very small as only three of the 137 donors 
had tumors. Two of the three were cadaver 
donors who had medulloblastomas. The 
third donor, also a cadaver, had had a 
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carcinoma of the colon resected 5 yr previ-
ously and was apparently free of cancer at 
the time of donation. The recipients subse-
quently developed apparently unrelated 
cancers-reticulum cell sarcoma in two 
instances and a leiomyosarcoma in one. 
Almost all of the patients received immu-
no suppression with Azathioprine and pred-
nisone. Other immunosuppressive meas-
ures used were ALG (38), actinomycin 
(39L roentgen therapy to the homograft 
(45L splenectomy (41), thymectomy (7), 
thymic irradiation (2), thoracic duct lymph 
drainage (7L cyclophosphamide (3), endo-
lymphatic radiation (1), total body irradia-
tion (1), methotrexate (1), 6-mercapto-
purine (1), and azaserine (1). 
Treatment of the epithelial lesions of 
skin, lip, and uterine cervix followed con-
ventional lines and was usually successful. 
Other epithelial tumors had a worse prog-
nosis and in most instances either caused 
or contributed to the patients' deaths. The 
overall survival in patients with epithelial 
cancers was 44 of 74 (59%). 
The outlook for recipients with mesen-
chymal neoplasms was more gloomy as 
only 11 of 48 patients (23%) are still 
living. Experience thus far is limited but it 
appears that conventional cancer therapy 
combined with reduction or cessation of 
immunosuppression may permit the pa-
tient's immune system to recover and resist 
the neoplasm. Five of the current survivors 
with highly malignant tumors were treated 
in this way with apparent eradication of 
the lesion and two more patients who died 
of infection or homograft failure were 
found to be free of cancer at autopsy. 
Transplanted Cancers 
Thirty-three patients received kidneys 
removed from donors who had cancer at 
the time of donation or who manifested 
evidence of the disease some months after-
ward. Subsequently, 19 recipients showed 
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no evidence of tumor either at autopsy or 
during follow-up from 1-32 mo. Presuma-
.bly these last kidneys were either free of 
cancer or transplanted malignant cells 
failed to become established in the host. 
In four patients, tumor was found in 
homografts removed within the first 16 
days after transplantation. Two more recip-
ients developed involvement by cancer of 
the kidney and adjacent structures, while 
eight additional patients also had evidence 
of distant spread. Five of these last eight 
patients died of the transplanted cancer and 
in the remaining three patients immuno-
suppression was discontinued and the neo-
plasms apparently underwent rejection. 
One is still well 97 mo posttransplantation 
despite further immunosuppressive therapy 
given for two subsequent renal transplants 
each of which functioned for 12-18 mo. 
The other two patients died several months 
after cessation of immunosuppression and 
no tumor was present at autopsy. 
Cancers Which Were Present Before 
Transplantation 
Fifty-three organ recipients had cancers 
within the 5 yr preceding transplantation. 
In 14 instances the tumor did not involve 
the organ undergoing replacement; while 
in 39 cases transplantation was performed 
for treatment of cancer of one or both kid-
neys (21 cases), primary or metastatic can-
cer of the liver (17 cases), and carcinoma of 
the larynx (one case). When transplanta-
tion was performed in the treatment of 
cancer the neoplasm appeared to be local-
ized and resectable so that there was hope 
of obtaining a "cure." 
Of the 53 recipients, 28 (53%) had no 
evidence of tumor in follow-up of 2-42 mo. 
Twenty-two patients (41 %) developed re-
current or metastatic cancers, and three 
(6 %) developed de novo tumors of a type 
completely different from the original neo-
plasms. 
IMMUNOSUPPRESSION AND CANCER 
PATIENTS WITH NONCANCEROUS 
DISEASES TREATED WITH 
IMMUNOSUPPRESSIVE AGENTS 
Thirty patients suffering from chronic 
cold hemagglutinin disease, rheumatoid 
arthritis, the nephrotic syndrome, systemic 
lupus erythematosus, ulcerative colitis, or 
psoriasis were treated with immunosup-
pressive agents and developed cancer. It 
might be argued that the immunosuppres-
sive agents played no role in the develop-
ment of the tumors in many of these dis-
orders as they are autoimmune diseases in 
which an increased incidence of cancer has 
been reported. However, this argument 
does not apply to psoriasis which is not 
usually associated with cancer. The devel-
opment of cancer in 20 psoriatic patients 
chronically treated with methotrexate or 
aminopterin must, therefore, be regarded 
with the gravest suspicion. 
PATIENTS WITH CANCERS WHO 
RECEIVED CANCER CHEMOTHERAPY 
Sixty-one patients received cancer 
chemotherapy for one type of neoplasm 
and subsequently developed a new cancer 
of a different type. Were the anticancer 
drugs the cause of the tumors or could 
these have occurred spontaneously? It is 
well recognized that a patient with one type 
of cancer is more prone to develop a second 
neoplasm. Furthermore, certain tumor asso-
ciations are widely accepted such as the 
relationship between solid lymphoma and 
lymphocytic leukemia or the termination of 
chronic myelogenous leukemia in acute 
myeloblastic leukemia. A few of the 61 
cases may have been of this type. However, 
certain associations are decidedly uncom-
mon and raise the strong suspicion that the 
cancer chemotherapeutic agents, while con-
trolling the original neoplasm, may have 
contributed to the development of the sec-
ond type of tumor. A strikingly example 
was the development of acute leukemia in 
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21 patients with multiple myeloma who 
were chronically treated with anticancer 
drugs, most commonly melphalan. Another 
is the development of a solid lymphoma in 
nine cases of chronic granulocytic leukemia. 
There are numerous additional cases in 
which a second tumor appeared while the 
patient was receiving chemotherapy for 
cancer. In many of these reports the au-
thors raised the question whether the sec.;. 
ond neoplasm was induced by the very 
agent which had controlled the first cancer. 
DISCUSSION 
In animal studies numerous experiments 
have elicited the paradox that agents which 
can destroy or arrest the growth of cancer 
may themselves be oncogenic. Do the anti-
cancer and immunosuppressive agents 
cause cancer in man, and if 50, by what 
mechanism? What is the effect of these 
agents on existing cancers? 
The answer to the first question is pro-
vided mainly by experience with organ 
homograft recipients. We have repeatedly 
reported a 5-6 % incidence of de novo 
cancers in organ homograft recipients 
treated with chronic immunosuppressive 
therapy.l-4 These findings are reinforced 
by experience with neoplasms inadvertently 
transplanted with kidneys obtained from 
donors with cancer. It is very rarely pos-
sible to transplant cancer cells successfully. 
from one healthy human to another as they 
are recognized as "foreign" by the host's 
defenses and are readily destroyed. How-
ever, if the normal defense mechanisms 
are impaired by chronic immunosuppres-
sion, it is possible for the transferred malig-
nant cells to become established in the 
homograft, invade the surrounding tissues, 
and metastasize Widely. If the immuno-
suppressive therapy is discontinued, the im-
mune defenses may recover and reject the 
cancer cells. This approach was successfully 
used in several cases reported in this paper. 
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Furthermore, it may also be applicable to 
the management of the more aggressive 
de novo tumors which arise posttransplan-
tation and which fail to respond to con-
ventional cancer therapy. 
The concept that tumors may arise in in-
dividuals under chronic immunosuppres-
sive therapy is further strengthened by 
reports concerning non transplant patients 
treated with these agents. This applies par-
ticularly to sufferers from psoriasis who 
received chronic treatment with metho:-
trexate or aminopterin. 
How do the immunosuppressive or can-
cer chemotherapeutic agents cause malig-
nant tumors? There are several possibili-
ties. First, the drugs may be directly on-
cogenic. Second, the compounds may po-
tentiate the effects of various environmen-
tal carcinogens such as tobacco, sunlight, 
or radiation. Third, the agents may cripple 
the surveillance function of the lympho-
reticular system by which potentially ma-
lignant mutant cells are normally elimi-
nated. Fourth, the weakened host defenses 
may permit oncogenic viruses to become 
established and cause malignant tumors. 
While there is unequivocal evidence that 
the anticancer and immunosuppressive 
agents may cause de novo neoplasms their 
effects on patients with preexisting tumors 
are not so clearly defined. In organ trans-
plant recipients with cancer there is a 41 % 
likelihood of recurrence or metastases of 
the original tumor and a 6 % incidence of 
unrelated de novo neoplasms. It is not 
possible to determine whether the former 
figure is merely a reflection of the natural 
history of the cancers or is contributed to 
by chronic immunosuppressive therapy. 
In the case of advanced cancers treated 
with chemotherapy there are reports sug-
gesting that, while the original cancer had 
been controlled, the long-term chemother-
apy may have caused new cancers. No 
doubt there are numerous additional cases 
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which have not been reported. The subject 
is a very complex one requiring considera-
tion of the increased likelihood of a patient 
with one cancer developing a second neo-
plasmj the tendency for one form of cancer 
to change to another related typej and 
the influence of other therapeutic agents, 
such as radiotherapy, which may be onco-
genic. In the present study the three most 
commonly used compounds were melpha-
lan, cyclophosphamide, and busulfan-all 
alkylating agents. These have radiomimetic 
actions and are known to be mutagenic 
and carcinogenic in laboratory animals. 
While cancer chemotherapy has had 
some notable successes, the overall results 
have been rather disappointing. These have 
been blamed on unresponsiveness of the 
tumor to a particular agent, or to the sub-
sequent development of resistance by the 
cancer cells, or to the toxic effects of the 
compounds used. Another factor, which 
has received relatively scant attention, is 
the prolonged immunosuppressive effect of 
the a:gents when administered continuously. 
Could this be the explanation for the ob-
servation that a better objective response 
and longer survival was observed when 
chemotherapy was given intermittently 
rather than continuously? 
The finding that cancer patients treated 
with chemotherapy may develop new 
tumors is more of academic than of prac-
tical importance and represents the price 
the patient has to pay for the hope of relief 
from the original cancer. Even so, several 
important lessons do emerge from this 
study. First, immunosuppressive agents 
should not be used in nonmalignant dis-
eases, such as psoriasis or rheumatoid ar-
thritis, unless all other forms of therapy 
have failed to provide relief. Second, in 
organ transplantation, donors with cancer 
should not be used except in cases with 
pr.imary tumors of the central nervous sys-
tem which seldom spread to other organs. 
IMMUNOSUPPRESSION AND CANCER 
Third, when a cancer arises in an immuno-
suppressed patient it may be useful to 
withdraw or reduce the immunosuppressive 
therapy in the hope that the host defenses 
may recover and resist the neoplasm. 
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Fourth, the studies emphasize the impor-
tance of the immune system in dealing with 
cancel" and suggest that research on immu-
notherapy should be vigorously pursued. 
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